Volume 19 Issue 1, March 2025

BioCanRx is leading the way in the translation, manufacture and adoption of immunotherapies in Canada to ensure that Canadian patients have access to this powerful therapeutic approach via clinical trials.

Find Therapeutics’ experienced leadership is developing a novel approach to repair myelin damage in multiple sclerosis, often associated with early visual impairment.

With its AI-powered technology platform and proprietary microbe collection, Kapoose Creek Bio is advancing a new wave of neuroactive drugs.

With obesity medicines now household names, the race is on amongst the pioneers and competitor companies to bring improved products to market.

MultiOmic Health is using a data-driven AI-enabled approach to develop tailored therapeutics for specific subpopulations of patients with metabolic syndrome-related conditions, which affect around half of the adult population worldwide.

UK-based DefiniGEN has developed iPSC-derived cell lines that can replace primary human hepatocytes for toxicity testing and accelerate the development of novel liver-targeted therapeutics.

Broad-reaching modalities such as ADCs, bi-specifics and radiopharmaceuticals were popular in 2024 and are likely to remain hot this year.

European biotech company Cellis has developed breakthrough platform technology to overcome the limitations of current solid-tumor treatments and provide life-changing therapies for cancer patients, advancing the field of precision oncology.

Transcenta is employing its unique, cutting-edge discovery technology to develop antibody-based therapies that address unmet medical needs in oncology, immunology and inflammation.

Aleta Biotherapeutics is using its novel technology platform to develop bespoke, multi-antigen-targeting biologics for a diverse range of indications, including B-cell cancers and solid tumors, improving outcomes in patient populations with high unmet need.

The need to get novel biologic modalities to the right place effectively and efficiently is highlighted in major recent deals around drug delivery platforms.

With its innovative VECTrans platform, Vect-Horus is enabling targeted drug delivery across the blood–brain barrier, potentially transforming the treatment of neurodegenerative disorders.

Current guidelines recommend transdermal delivery of testosterone for post-menopausal women seeking treatment for hypoactive sexual desire disorder. Medherant’s TEPI patch has been developed to fill this unmet medical need.